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The 2009 H1N1 influenza pandemic initially affected Mexico from April 2009 to July 2010.
By August 2010, a fourth of the population had received the monovalent vaccine against
the pandemic virus (A(H1N1)pdm09). To assess the proportion of the Mexican population
who remained potentially susceptible to infection throughout the summer of 2010, we
estimated the population seroprevalence to A(H1N1)pdm09 in a serosurvey of blood
donors.
Methods
We evaluated baseline cross-reactivity to the pandemic strain and set the threshold for
seropositivity using pre-pandemic (2005–2008) stored serum samples and sera from con-
firmed A(H1N1)pdm09 infected individuals. Between June and September 2010, a conve-
nience sample serosurvey of adult blood donors, children, and adolescents was conducted
in six states of Mexico. Sera were tested by the microneutralization (MN) and hemagglutina-
tion inhibition (HI) assays, and regarded seropositive if antibody titers were equal or
exceeded 1:40 for MN and 1:20 for HI. Age-standardized seroprevalence were calculated
using the 2010 National Census population.
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Results
Sera from 1,484 individuals were analyzed; 1,363 (92%) were blood donors, and 121 (8%)
children or adolescents aged19 years. Mean age (standard deviation) was 31.4 (11.5)
years, and 276 (19%) were women. A total of 516 (35%) participants declared history of
influenza vaccination after April 2009. The age-standardized seroprevalence to A(H1N1)
pdm09 was 48% by the MN and 41% by the HI assays, respectively. The youngest quintile,
aged 1 to 22 years, had the highest the seroprevalence; 61% (95% confidence interval [CI]:
56, 66%) for MN, and 56% (95% CI: 51, 62%) for HI.
Conclusions
Despite high transmission of A(H1N1)pdm09 observed immediately after its emergence
and extensive vaccination, over a half of the Mexican population remained potentially sus-
ceptible to A(H1N1)pdm09 infection. Subsequent influenza seasons with high transmission
of A(H1N1)pdm09, as 2011–2012 and 2013–2014, are compatible with these findings.
Background
The 2009 H1N1 influenza pandemic initially hit Mexico from April 2009 to July 2010. [1]
Thirty million doses of the monovalent vaccine against the pandemic H1N1 virus (A(H1N1)
pdm09) were delivered to the Mexican population, primarily targeting high-risk groups, from
February to August 2010.
Cross-sectional serosurveys of influenza help estimate crude and age-specific prevalence
proportions, and assess the probability and size of future epidemics. [2–4] Comparing results
across different studies may be challenging as estimates of influenza seroprevalence vary due to
dissimilar study populations, time of sera collection, analytical methods, and classification
thresholds. [2,5] Seroprevalence estimates may also differ by geographic area even within the
same country. To our knowledge, little published information exists on the post-pandemic
seroprevalence to A(H1N1)pdm09 virus in Mexico. Only one A(H1N1)pdm09 seroprevalence
study measured antibodies by enzyme-linked immunosorbent assay, in late 2009, however the
focus was only on persons living in the city of Monterrey, Nuevo León. [6] National public
health planning requires assessing susceptibility to infection in representative populations. [7]
To characterize the population immunity to A(H1N1)pdm09 throughout the summer of
2010, we conducted a national serosurvey in six states of Mexico and estimated the proportion
of the population with antibodies to influenza A(H1N1)pdm09 as of 2010, using the well-char-
acterized hemagglutination-inhibition assay (HI) and microneutralization assay (MN). [8] To
further evaluate the contribution of influenza vaccination to the population immunity, we also
collected information on influenza vaccination coverage. One year after the emergence of the
pandemic, over half of the Mexican population had anti-influenza antibody titers below the
threshold of immunity, rendering them potentially susceptible to A(H1N1)pdm09 infection.
Methods
Survey design
To assess the seroprevalence of antibodies to A(H1N1)pdm09 in Mexico, post-pandemic
serum samples were collected from 1,484 subjects residing in six states throughout Mexico:
Nuevo León and Sonora (in the north), Veracruz (east), Campeche and Chiapas (south), and
Mexico City (center). Age of subjects ranged from 1 to 65 years. Sera were collected from June
Seroprevalence of Influenza A(H1N1)pdm09 in Mexico
PLOS ONE | DOI:10.1371/journal.pone.0150428 March 22, 2016 2 / 9
Competing Interests: The authors have declared
that no competing interests exist.
Abbreviations: A(H1N1)pdm09, Pandemic 2009
influenza virus H1N1; 95% CI, 95% Confidence
interval; CDC, US Centers for Disease Prevention
and Control; HI, Hemagglutination-inhibition assay;
InDRE, Institute of Diagnosis and Epidemiological
Reference; MN, Microneutralization assay; PR,
Prevalence ratio.
through September 2010, more than a year after the outset of the epidemic and during a vacci-
nation campaign that by October 2010 had delivered 30 million doses of monovalent vaccine
against influenza A(H1N1)pdm09, but prior to the 2010/2011 influenza season. The majority
of sera (n = 1,363) were collected from adult blood donors. Additional sera (n = 121) were col-
lected from children and adolescents (aged 19 years) who underwent pre-operatory testing
or diagnostic procedures for non-febrile, non-respiratory illness at emergency rooms of public
hospitals in Mexico City. Trained personnel of blood banks and participant hospitals collected
blood samples using standard procedures.
Study participants were administered a questionnaire to assess their history of acute respira-
tory illness (i.e., cough, sore throat, and fever), close contact with a person with confirmed
influenza, and influenza vaccination, all between April 2009 and the date of the interview.
Those who reported receiving influenza vaccination were further asked about the type of vac-
cine (i.e., the monovalent A(H1N1)pdm09 vaccine, the 2009–2010 trivalent seasonal vaccine
for the Northern hemisphere, or both). Participants provided written informed consent them-
selves or, in the case of children, by their parents. The collection and testing of serum samples
at InDRE was considered to be a public health, non-research activity that was exempt from
human subject review. Authors only accessed de-identified records from study subjects.
Titer threshold definition
To determine the sensitivity of the serological assays, paired acute and convalescent (13–75
days after symptom onset) sera from 174 individuals, confirmed to be infected with A(H1N1)
pdm2009 virus by real-time reverse-transcription polymerase chain reaction, were tested. Sera
were collected from April through July 2009. Participants were residents of Mexico City,
Durango, Estado de Mexico, and Queretaro, and their age ranged from 8 months to 75 years.
Sensitivity was estimated only on convalescent sera.
To determine the specificity of the serological assays, we analyzed 438 stored serum samples
collected between January 2007 thought November 2008 from febrile individuals, aged 0 to 96
years. who tested negative for dengue virus infection. Because the number of individuals over
60 years of age was small, 76 additional samples were obtained from adults aged 60 to 88 years
who participated in the Mexican National Health Survey conducted in 2005.
Laboratory procedures
Sera were analyzed with the MN and HI assays at the Institute of Diagnosis and Epidemiologi-
cal Reference (InDRE; Mexico City, Mexico) following standard protocols, using an A/Califor-
nia/7/2009-like H1N1 influenza virus, which was propagated in 10 to 11 day-old embryonated
chicken eggs. [9]
For the HI assay, sera were treated with receptor-destroying enzyme (RDE; Denke-Seiken,
Japan) and, for both assays; sera were heat-inactivated at 56°C for 30 minutes before testing.
Sera containing nonspecific agglutinins were pre-adsorbed with turkey erythrocytes before
testing by HI. HI testing was performed using 0.5% turkey erythrocytes. Serial two-fold dilu-
tions of serum were tested in duplicate starting at the 1:10 dilution. For both assays, antibody
titers were expressed as the reciprocal of the highest dilution of serum resulting in 50% neu-
tralization or complete hemagglutination inhibition. Titers of<10 were reported as 5.
The geometric mean of the duplicates was considered as the antibody titer for each sample.
Thresholds for the MN and HI seropositivity were defined as the titer cut-off points, larger
than the limit of detection, that maximize the sum of sensitivity and specificity when testing
separate groups of positive and negative sera. Antibody titers of MN 1:40 or HI 1:20 were
identified as optimal thresholds, with sensitivity of 89% and 63%, and specificity of 85% and
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98%, respectively (Table A in S1 File). Pre-pandemic sera were also tested at the Influenza Divi-
sion, US Centers for Disease Control and Prevention (CDC; Atlanta, Georgia). Both InDRE
and CDC reported the same MN and HI titers for an International Standard (IS) for antibody
to A(H1N1)pdm09 (09/194) which was tested side-by-side with the sera samples. [10] There-
fore, no adjustment of titers was required.
Statistical analysis
The mean proportion of seropositive individuals was the primary measure of prevalence in the
study population. Prevalence was estimated overall and for quintiles of age with limits at: 1 to
22 years (n = 312), 23 to 28 years (n = 309), 29 to 34 years (n = 301), 35 to 41 years (n = 273),
and 42 to 65 years (n = 289). We used multivariate log-binomial generalized linear models,
with robust standard errors, to estimate prevalence ratios (PR) adjusted by sex, age, self-
reported history of vaccination, and self-reported respiratory illness. Age quintiles were
included in the model as indicators. Age-standardized seroprevalence for the age range of the
survey population (1 to 65 years) was estimated by the direct method using the 2010 Mexican
National Census (http://www.inegi.org.mx/est/contenidos/Proyectos/ccpv/) as the reference
population. Analyses were conducted in Stata/SE 13.1 for Mac (Stata Corp., College Station,
TX).
Results
Characteristics of the survey population
A total of 1,484 individuals answered the survey and provided a blood sample for testing; 1,363
(92%) were blood donors and 121 (8%) were children or adolescents aged 19 years. Mean
age (standard deviation) was 31.4 (11.5) years, and 276 (19%) were women. (Table 1)
History of influenza vaccination
Of the 1,484 participants, 516 (35%) reported having being vaccinated against influenza
between April 2009 and the date of the survey. The proportion of vaccinated individuals varied
across states, ranging from 25% in Sonora to 45% in Campeche. (Table 1) Among the vacci-
nated, 99 (19%) indicated receiving the monovalent A(H1N1)pdm09 vaccine, 167 (32%) the
2009–2010 seasonal trivalent vaccine for the Northern hemisphere, 56 (11%) both vaccines,
and 194 (38%) participants did not specify the vaccine type they had received (Table B in S1
File).
The proportion of vaccinated individuals who received the A(H1N1)pdm09 monovalent
vaccine ranged from 7% in Chiapas to 38% in Campeche and Nuevo León. (Table B in S1 File).
Study participants who received the A(H1N1)pdm09 monovalent vaccine were evenly distrib-
uted across age groups. (Table C in S1 File)
History of acute respiratory illness
A total of 111 (8%) individuals reported history of acute respiratory illness after April 2009.
The frequency of self-reported respiratory illness was larger in first age quintile (i.e., 1–22
years) than in all other age quintiles PR: 4.3 (95% confidence interval [CI]: 3.0, 6.1). Compared
to those who reported no, or unknown recent vaccination, individuals who reported recent his-
tory of influenza vaccination were more likely to also report a history of recent acute respira-
tory illness; PR: 1.8 (95% CI: 1.2, 2.5).
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Seropositive proportions to A(H1N1)pdm09 in the survey population
Using titer thresholds of MN 1:40 or HI 1:20, the crude estimated proportions of seroposi-
tives to the A(H1N1)pdm09 virus in the survey population, were 43% (95% CI: 41, 46%) and
35% (95% CI: 32, 37%), respectively. The youngest quintile of age (1–22 years) had the highest
proportion of seropositives (61%, 95% CI: 56, 66%; and 56%, 95% CI: 51, 62%) by MN and HI,
respectively. (Table 2) Regardless of age, proportions of seropositives were higher in those with
Table 2. Number and proportion of the 1,484 participants who tested positive to influenza A(H1N1)pdm09 at the MN 1:40 and HI 1:20 thresh-
olds, by quintiles of age.
Age range, years Number Age, years Number and percentage of seropositive individuals *
MN  1:40 HI  1:20
Median IQR† n % 95% CI n % 95% CI
1–22 312 19 14, 21 190 61 56, 66 175 56 51, 62
23–28 309 25 24, 27 135 44 38, 49 108 35 30, 40
29–34 301 31 30, 33 106 35 30, 41 76 25 20, 30
35–41 273 38 36, 40 105 39 33, 44 76 28 23, 33
42–65 289 47 44, 51 102 35 30, 41 80 28 23, 33
Overall 1,484 31 24, 39 638 43 41,46 43 35 32, 37
The inﬂuenza A(H1N1)pdm09 serosurvey in blood donors; Mexico, June–September 2010.
* Percentages may not add up to 100 because of rounding.
† IQR = interquartile range
doi:10.1371/journal.pone.0150428.t002
Table 1. Characteristics of 1,484 participants of the influenza A(H1N1)pdm09 serosurvey in blood donors; Mexico, June–September 2010.




(n = 516; 35%) (n = 949; 64%) (n = 19; 1%) (n = 1,484)
Mean, Standard deviation
Age, years 30.7 12.0 31.9 11.1 25.3 12.9 31.4 11.5
Number, %
Women 104 20 166 18 6 32 276 19
State of residency
Campeche 53 10 66 7 0 0 119 8
Chiapas 76 15 153 16 2 11 231 16
Mexico City 194 38 378 40 12 63 584 39
Nuevo Leon 63 12 82 9 2 11 147 10
Sonora 38 7 112 12 0 0 150 10
Veracruz 92 18 158 17 3 16 253 17
History of respiratory illness † 54 11 56 6 1 5 111 8
Recent exposure to a person with respiratory illness § 10 1 13 3 0 0 23 2
* Percentages may not add up to 100 because of rounding.
† Sixteen individuals who reported unknown recent history of respiratory illness were classiﬁed as with no recent respiratory illness. One of these reported
recent history of inﬂuenza vaccination, two reported unknown history of inﬂuenza vaccination, and 13 declared no recent inﬂuenza vaccination.
§ Deﬁned as self-reported close contact (i.e., at household) with a person having respiratory symptoms within the two weeks of the survey. A total of 46
individuals that reported unknown contact to a person with respiratory illness were classiﬁed as no contact.
doi:10.1371/journal.pone.0150428.t001
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self-reported recent history of influenza vaccination than in those without or unknown vacci-
nation history; PR = 2.0 (95% CI: 1.8, 2.3) at MN 1:40, and 2.2 (95% CI: 1.9, 2.5) at HI 20.
Qualitatively similar results were observed when comparing seropositivity in persons who
received monovalent A(H1N1)pdm09 vaccine, alone or with the seasonal trivalent influenza
vaccine, to those who did not received either vaccine (Table D in S1 File).
Age-standardized seroprevalence of A(H1N1)pdm09
The 2010 National Population Census estimated 112,336,536 inhabitants in Mexico. Of these,
102,615,001 million persons were aged 1 to 65 years and distributed across the quintiles of the
survey population as follows: 47,610,247 million (46%) were aged 1 to 22 years; 11,023,229 mil-
lion (11%) were aged 23 to 28 years; 10,076,528 million (10%) were aged 29 to 34 years;
11,252,026 million (11%) were aged 35 to 41 years; and 22,652,971 million (22%) were aged 42
to 65 years. The age-standardized seroprevalence to A(H1N1)pdm09 in the census population
was 48% for the MN and 41% for the HI assays; which were 12 and 17% higher, respectively,
than the corresponding crude seropositive proportions in the survey population. (Table 3)
Discussion
One year after the emergence of the 2009 H1N1 influenza pandemic and delivery of 30 million
doses of the monovalent A(H1N1)pdm09 vaccine, over half of the Mexican population had
anti-influenza antibody titers below the threshold of seropositivity used in this study. Children
and adolescents had the highest seroprevalence proportion, which is consistent with records of
disease surveillance showing this age-group had the highest cumulative incidence of A(H1N1)
pdm09 confirmed infection in Mexico within the first year of the emergence of the 2009 influ-
enza pandemic [11,12].
In this study, all 121 children and adolescents (aged 19 years), who were not blood
donors, resided in Mexico City. They represented 8% of the study population, but encompassed
58% of the youngest quintile. Therefore, the highest seroprevalence in this age group may be
partially biased by over-representation of some geographic areas in Mexico. Nevertheless, the
Table 3. Estimated number of seropositive individuals and age-standardized population seroprevalence to influenza A(H1N1)pdm09, at the
MN 1:40 and HI 1:20 thresholds, for the age range of the survey.






n Mean (95% CI)
MN  1:40 HI  1:20 MN  1:40 HI  1:20
1–22 47,610,247 0.464 28,993,418 26,704,464 61 56, 66 56 51, 62
23–28 11,023,229 0.107 4,815,974 3,852,779 44 38, 49 35 30, 40
29–34 10,076,528 0.098 3,548,545 2,544,240 35 30, 41 25 20, 30
35–41 11,252,026 0.110 4,327,703 3,132,432 39 33, 44 28 22, 33
42–65 22,652,971 0.221 7,995,167 6,270,719 35 30, 41 28 23, 33
Age-standardized 102,615,001 1.000 49,680,804 42,504,632 48 41
The inﬂuenza A(H1N1)pdm09 serosurvey in blood donors; Mexico, June–September 2010.
* Age categories were chosen at the same age limits of quintiles in the study population
† Number of seropositive individuals were back-calculated from the estimated proportions
doi:10.1371/journal.pone.0150428.t003
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only previously published influenza serosurvey in Mexico, conducted in a single city (Monter-
rey, Nuevo León) [6] attained similar findings, as did most serosurveys conducted in other
countries from 2010 to 2012. All these studies estimated highest seroprevalence of A(H1N1)
pdm2009 in the population aged 20 years.[4] The skewed age distribution of each study pop-
ulation must be considered when comparing estimates of seroprevalence for influenza A
(H1N1)pdm09 across countries. We stratified results by age quintiles to attain enough statisti-
cal power for ascertaining age trends in seroprevalence. Seroprevalence proportions for alter-
native age categories used in other published serosurveys of influenza A(H1N1)pdm09 (Tables
E and F in S1 File) showed similar age distribution. Incomplete control of confounding by age
may be of concern regardless of the selection of age categories because age does not distribute
uniformly within categories. To remove confounding by age, we estimated the age-standard-
ized seroprevalence, which was up to 17% higher than the unadjusted seropositive proportion
in the survey population.
Our use of the standard MN and HI assays helps compare seroprevalence estimates to that
in other serosurveys. Although an HI titer of 40 is commonly used as a marker of immunity
to A(H1N1)pdm09, [13] our data suggest that this titer threshold may underestimate the num-
ber of infected individuals. As in other studies, [9] our HI assay alone was more specific for
detecting antibody to A(H1N1)pdm09 while the MN was the most sensitive assay. The combi-
nation of threshold titers (MN 40 or HI 20) yielded the highest joint sensitivity and speci-
ficity to accurately identify individuals who were likely infected by the 2009 virus in the
absence of demonstrable seroconversion in paired sera. Despite this, using seropositivity alone
may underestimate the true rate of seroconversion because some persons infected with the A
(H1N1)pdm09 virus may not develop detectable serological responses, and also because anti-
body titers elicited by infection or vaccine may subsequently decline below the limit of serologi-
cal detection. Assuming incomplete detection of seropositive individuals, our findings of
detectable antibodies titers in almost half of the population provides a conservative estimate of
seroprevalence.
This study encompassed blood donors, who generally are healthy persons between 18 and
65 years of age. Other than the 22 children aged 12 to 36 months, this survey did not include
individuals in the high-risk categories defined by the Mexican National Council for Vaccina-
tion as targets of the A(H1N1)pdm09 monovalent or seasonal influenza vaccines, in the sum-
mer of 2009. Such high-risk groups included: healthy persons aged 6 to 36 months or older
than 65 years, pregnant women, the extremely obese; persons with diabetes mellitus, chronic
heart or pulmonary disease; and other immunocompromised individuals. More than a third of
the participants in all age categories self-reported history of influenza vaccination after April
2009, either with the monovalent A(H1N1)pdm09 or the trivalent seasonal influenza vaccines
(Table C in S1 File) indicating that, despite specific high-risk groups were defined in Mexico as
targets for vaccination, these vaccines were administered different from planned, reaching also
healthy persons of intermediate ages.
Self-reported history of pandemic influenza vaccination was significantly associated with
higher age-adjusted seroprevalence, pointing to the expected role of vaccination in increasing
immunity to influenza, even one year after the emergence of the epidemic. [12] Persons immu-
nized with the 2009–2010 seasonal trivalent vaccine, which lacked the A(H1N1)pdm09 anti-
gen, also exhibited increased seropositivity to this virus although at significantly lower
proportion than those who received the A(H1N1)pdm09 monovalent vaccine. While we can-
not rule out that this effect, may in part, be attributed to a misidentification of vaccine type by
interviewees, as both vaccines were administered a short time apart, other studies have
reported increments in A(H1N1)pdm09 antibody titers in individuals that received previous
seasonal influenza vaccines [14,15].
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Furthermore, participants of the survey who reported history of acute respiratory illness since
the outset of the 2009 pandemic were more likely to be seropositive to influenza A(H1N1)
pdm09, but this was unapparent upon adjusting by age. This finding suggests that the purported
association of respiratory illness with seropositivity may have resulted from confounding by age
as younger individuals, particularly children aged<10 years who have the highest proportions of
seropositivity are also known to experience higher frequency of respiratory infections other than
influenza. Because both, history of respiratory disease and influenza vaccination were self-
reported and collected retrospectively, we cannot rule out the possibility for recall bias.
We found no significant variability of seropositive proportions across the six states of
Mexico analyzed in this study, which is also consistent with the findings of surveillance show-
ing that one year after the onset of the influenza epidemic, the A(H1N1)pdm09 virus had
reached all regions with similar intensity. [1]
An important limitation of this study is the inclusion of a convenience sample of blood
donors and healthy children eligible for surgical procedures, which may not represent the
entire Mexican population as it does not include individuals at high risk of influenza. Conse-
quently, the study may have underestimated the seroprevalence. Nonetheless, this study pro-
vides evidence that despite the high transmission of A(H1N1)pdm09 observed during the first
year of its emergence and extensive vaccination, over a half of the population of Mexico had no
or low levels of neutralizing antibodies against A(H1N1)pdm09 virus, rendering them poten-
tially susceptible to A(H1N1)pdm09 infection. Subsequent influenza seasons with high trans-
mission of A(H1N1)pdm09, as 2011–2012 and 2013–2014, are compatible with these findings
and further support the value of influenza seroprevalence studies for assessing the risk of influ-
enza transmission. [16,17]
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